EUCTR2011-001863-39-AT
Active, not recruiting
Not Applicable
A multi-center study of the safety and effect on disease activity of Tocilizumab (TCZ) in combination with Methotrexate (MTX) versus Tocilizumab monotheraphy in patients with mild to moderate rheumatoid arthritis, with inadequate response to MTX (defined as DAS 28 = 4,5 and > 2,6) - OPTIMISE
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Roche Austria GmbH
- Status
- Active, not recruiting
- Last Updated
- 12 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •\- Diagnosis of RA of \= 1 years duration (or radiologic evidence of RA if diagnosis of RA \< 1 year) and mild to moderate disease activity at screening (defined as DAS 28 \= 4,5 and \> 2,6\)
- •\- Patients currently receiving MTX for at least 12 weeks and who have received MTX at a stable dose of at least 15mg/week for at least 6 weeks prior to treatment (day 1\).
- •Patients with a history of parenteral (subcutaneous or intramuscular) MTX prior to baseline are eligible. However, prior to treatment (day 1\) these patients must have been on a stable dose of oral MTX of at least 15 mg/week for at least 6 weeks
- •\- Age \= 18 years.
- •\- Body weight \< 150kg
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range 120
- •F.1\.3 Elderly (\>\=65 years) yes
Exclusion Criteria
- •\- Rheumatic autoimmune disease other than RA
- •\- Functional class IV as defined by the ACR Classification of Functional Status in RA
- •\- Treatment with a biologic agent at any time prior to baseline.
- •\- Treatment with traditional non\-biologic DMARDs other than MTX within 1 month (for leflunomide 3 months) prior to baseline
- •\- History of severe allergic or anaphylactic reactions to human, humanized, or murine monoclonal antibodies
- •\- Evidence of serious uncontrolled concomitant cardiovascular, nervous system, pulmonary (including obstructive pulmonary disease), renal, hepatic, endocrine (including uncontrolled diabetes mellitus) or GI disease
- •\- Known active current or history of recurrent bacterial, viral, fungal, mycobacterial or other infections
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Multicenter study for the efficacy and safety of DTN(distal tibia nail) in the trearment of fractures of the distal tibia.JPRN-UMIN000025272Okayama University12
Unknown
Phase 3
A multicenter investigative study of the safety and efficacy of long-term administration of aripiprazole in combination with mood stabilizer for the treatment of patients with bipolar disorder experiencing a manic or mixed episodeAcute manic and mixed episodes associated with Bipolar I DisorderJPRN-jRCT2080220516Otsuka Pharmaceutical Co., Ltd.
Completed
Not Applicable
A Multicenter study of the safety and efficacy of Asfotase Alfa (ALXN1215) (Human Recombinant Tissue Nonspecific Alkaline Phosphatase Fusion Protein) in patients with hypophosphatasia (HPP)JPRN-UMIN000014816HPP study group20
Completed
Not Applicable
A multicentre study of the safety and efficacy of N-acetylcysteine in the treatment of acute liver failure in paediatric patients not caused by acetaminopheTopic: Medicines for Children Research NetworkSubtopic: All DiagnosesDisease: All DiseasesDigestive SystemAcute liver failureISRCTN36658311King's College Hospital NHS Foundation Trust (UK)28
Completed
Not Applicable
A multi-center study of the safety and efficacy of the percutaneous transvenous mitral annuloplasty system to reduce mitral valve regurgitation in patients with heart failure.mitral regurgitationmitral valve leakage10046973NL-OMON33252Viacor Inc.14